TISIDB

Summary
Symbol	MET
Name	MET proto-oncogene, receptor tyrosine kinase
Aliases	HGFR; DFNB97; hepatocyte growth factor receptor; met proto-oncogene; AUTS9; c-Met; HGF receptor; HGF/SF rece ......
Chromosomal Location	7q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 3: Secreted.
Domain	PF07714 Protein tyrosine kinase PF01437 Plexin repeat PF01403 Sema domain PF01833 IPT/TIG domain
Function	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity). ; FUNCTION: Acts as a receptor for Listeria internalin inlB, mediating entry of the pathogen into cells.

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0001667 ameboidal-type cell migration GO:0001763 morphogenesis of a branching structure GO:0001885 endothelial cell development GO:0001886 endothelial cell morphogenesis GO:0002064 epithelial cell development GO:0003158 endothelium development GO:0003382 epithelial cell morphogenesis GO:0006914 autophagy GO:0006979 response to oxidative stress GO:0010035 response to inorganic substance GO:0010421 hydrogen peroxide-mediated programmed cell death GO:0010506 regulation of autophagy GO:0010507 negative regulation of autophagy GO:0010594 regulation of endothelial cell migration GO:0010595 positive regulation of endothelial cell migration GO:0010631 epithelial cell migration GO:0010632 regulation of epithelial cell migration GO:0010634 positive regulation of epithelial cell migration GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0030335 positive regulation of cell migration GO:0032103 positive regulation of response to external stimulus GO:0034599 cellular response to oxidative stress GO:0034614 cellular response to reactive oxygen species GO:0035239 tube morphogenesis GO:0035767 endothelial cell chemotaxis GO:0036473 cell death in response to oxidative stress GO:0036474 cell death in response to hydrogen peroxide GO:0040017 positive regulation of locomotion GO:0042542 response to hydrogen peroxide GO:0043542 endothelial cell migration GO:0045446 endothelial cell differentiation GO:0048012 hepatocyte growth factor receptor signaling pathway GO:0048754 branching morphogenesis of an epithelial tube GO:0050918 positive chemotaxis GO:0050920 regulation of chemotaxis GO:0050921 positive regulation of chemotaxis GO:0051272 positive regulation of cellular component movement GO:0060326 cell chemotaxis GO:0060562 epithelial tube morphogenesis GO:0061138 morphogenesis of a branching epithelium GO:0070301 cellular response to hydrogen peroxide GO:0071526 semaphorin-plexin signaling pathway GO:0090130 tissue migration GO:0090132 epithelium migration GO:0097468 programmed cell death in response to reactive oxygen species GO:1900407 regulation of cellular response to oxidative stress GO:1900408 negative regulation of cellular response to oxidative stress GO:1901031 regulation of response to reactive oxygen species GO:1901032 negative regulation of response to reactive oxygen species GO:1901298 regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1902882 regulation of response to oxidative stress GO:1902883 negative regulation of response to oxidative stress GO:1903201 regulation of oxidative stress-induced cell death GO:1903202 negative regulation of oxidative stress-induced cell death GO:1903205 regulation of hydrogen peroxide-induced cell death GO:1903206 negative regulation of hydrogen peroxide-induced cell death GO:2000147 positive regulation of cell motility GO:2001026 regulation of endothelial cell chemotaxis GO:2001028 positive regulation of endothelial cell chemotaxis
Molecular Function	GO:0004713 protein tyrosine kinase activity GO:0004714 transmembrane receptor protein tyrosine kinase activity GO:0005008 hepatocyte growth factor-activated receptor activity GO:0019199 transmembrane receptor protein kinase activity GO:0019902 phosphatase binding GO:0019903 protein phosphatase binding
Cellular Component	GO:0009925 basal plasma membrane GO:0016323 basolateral plasma membrane GO:0045178 basal part of cell

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04014 Ras signaling pathway hsa04015 Rap1 signaling pathway hsa04060 Cytokine-cytokine receptor interaction hsa04144 Endocytosis hsa04151 PI3K-Akt signaling pathway hsa04360 Axon guidance hsa04510 Focal adhesion hsa04520 Adherens junction
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-1280218: Adaptive Immune System R-HSA-422475: Axon guidance R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-186763: Downstream signal transduction R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR) R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-180292: GAB1 signalosome R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-5663205: Infectious disease R-HSA-8875360: InlB-mediated entry of Listeria monocytogenes into host cell R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-8876384: Listeria monocytogenes entry into host cells R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-6806942: MET Receptor Activation R-HSA-8851907: MET activates PI3K/AKT signaling R-HSA-8874081: MET activates PTK2 signaling R-HSA-8865999: MET activates PTPN11 R-HSA-8875555: MET activates RAP1 and RAC1 R-HSA-8851805: MET activates RAS signaling R-HSA-8875791: MET activates STAT3 R-HSA-8875513: MET interacts with TNS proteins R-HSA-8875878: MET promotes cell motility R-HSA-8875656: MET receptor recycling R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-6807004: Negative regulation of MET activity R-HSA-199418: Negative regulation of the PI3K/AKT network R-HSA-2219528: PI3K/AKT Signaling in Cancer R-HSA-198203: PI3K/AKT activation R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling R-HSA-1257604: PIP3 activates AKT signaling R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-400685: Sema4D in semaphorin signaling R-HSA-416550: Sema4D mediated inhibition of cell attachment and migration R-HSA-373755: Semaphorin interactions R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-6806834: Signaling by MET R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-983705: Signaling by the B Cell Receptor (BCR) R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04144 Endocytosis
hsa04151 PI3K-Akt signaling pathway
hsa04360 Axon guidance
hsa04510 Focal adhesion
hsa04520 Adherens junction

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-180292: GAB1 signalosome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-8875360: InlB-mediated entry of Listeria monocytogenes into host cell
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-8876384: Listeria monocytogenes entry into host cells
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-6806942: MET Receptor Activation
R-HSA-8851907: MET activates PI3K/AKT signaling
R-HSA-8874081: MET activates PTK2 signaling
R-HSA-8865999: MET activates PTPN11
R-HSA-8875555: MET activates RAP1 and RAC1
R-HSA-8851805: MET activates RAS signaling
R-HSA-8875791: MET activates STAT3
R-HSA-8875513: MET interacts with TNS proteins
R-HSA-8875878: MET promotes cell motility
R-HSA-8875656: MET receptor recycling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-6807004: Negative regulation of MET activity
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-400685: Sema4D in semaphorin signaling
R-HSA-416550: Sema4D mediated inhibition of cell attachment and migration
R-HSA-373755: Semaphorin interactions
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-6806834: Signaling by MET
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation

Summary
Symbol	MET
Name	MET proto-oncogene, receptor tyrosine kinase
Aliases	HGFR; DFNB97; hepatocyte growth factor receptor; met proto-oncogene; AUTS9; c-Met; HGF receptor; HGF/SF rece ......
Chromosomal Location	7q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MET and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between MET and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24561793	Chronic Lymphocytic Leukemia	Inhibit immunity	Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Hepatocyte growth factor may thus have a dual pathophysiological role: directly through enhancement of survival of the leukemic clone and indirectly by favoring T-cell immunosuppression.
29631966	adenocarcinomas; squamous Cell Carcinoma	Inhibit immunity immunotherapy target	High MET expression correlated with activation markers of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathways only in cases without Kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), v-Raf murine sarcoma viral oncogene homolog B (BRAF), anaplastic lymphoma kinase (ALK) and proto-oncogene tyrosine-protein kinase ROS (ROS1) aberrations.

Summary
Symbol	MET
Name	MET proto-oncogene, receptor tyrosine kinase
Aliases	HGFR; DFNB97; hepatocyte growth factor receptor; met proto-oncogene; AUTS9; c-Met; HGF receptor; HGF/SF rece ......
Chromosomal Location	7q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MET in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	Total # shRNA with >= 4-fold: 3	Resistant to T-cell proliferation

Summary
Symbol	MET
Name	MET proto-oncogene, receptor tyrosine kinase
Aliases	HGFR; DFNB97; hepatocyte growth factor receptor; met proto-oncogene; AUTS9; c-Met; HGF receptor; HGF/SF rece ......
Chromosomal Location	7q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MET in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.133	0.865
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.049	0.98
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.185	0.912
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.032	0.962
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.385	0.865
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.411	0.889
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.014	0.985
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.785	0.692
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.719	0.758
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.013	0.994
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.417	0.88
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.053	0.73

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MET in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	2.7	8.4	0.12
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	1.7	9.4	0.0895
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	23.8	11.8	12	0.427
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	30.8	18.2	12.6	0.649
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	12.5	-12.5	0.52
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	10.5	3.7	6.8	0.393
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	7.7	5.9	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	15.4	-6.3	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	16.7	-16.7	1

Summary
Symbol	MET
Name	MET proto-oncogene, receptor tyrosine kinase
Aliases	HGFR; DFNB97; hepatocyte growth factor receptor; met proto-oncogene; AUTS9; c-Met; HGF receptor; HGF/SF rece ......
Chromosomal Location	7q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MET. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MET
Name	MET proto-oncogene, receptor tyrosine kinase
Aliases	HGFR; DFNB97; hepatocyte growth factor receptor; met proto-oncogene; AUTS9; c-Met; HGF receptor; HGF/SF rece ......
Chromosomal Location	7q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MET. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MET. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MET
Name	MET proto-oncogene, receptor tyrosine kinase
Aliases	HGFR; DFNB97; hepatocyte growth factor receptor; met proto-oncogene; AUTS9; c-Met; HGF receptor; HGF/SF rece ......
Chromosomal Location	7q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MET. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MET
Name	MET proto-oncogene, receptor tyrosine kinase
Aliases	HGFR; DFNB97; hepatocyte growth factor receptor; met proto-oncogene; AUTS9; c-Met; HGF receptor; HGF/SF rece ......
Chromosomal Location	7q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MET expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MET
Name	MET proto-oncogene, receptor tyrosine kinase
Aliases	HGFR; DFNB97; hepatocyte growth factor receptor; met proto-oncogene; AUTS9; c-Met; HGF receptor; HGF/SF rece ......
Chromosomal Location	7q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MET and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MET
Name	MET proto-oncogene, receptor tyrosine kinase
Aliases	HGFR; DFNB97; hepatocyte growth factor receptor; met proto-oncogene; AUTS9; c-Met; HGF receptor; HGF/SF rece ......
Chromosomal Location	7q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MET collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting MET.

ID	Name	Drug Type	Targets	#Targets
DB02152	K-252a	Small Molecule	MAP2K1, MET	2
DB06896	1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide	Small Molecule	MET	1
DB06995	N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide	Small Molecule	MET	1
DB06997	2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide	Small Molecule	MET	1
DB07369	N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide	Small Molecule	MET	1
DB07969	3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol	Small Molecule	MET	1
DB08584	6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline	Small Molecule	MET	1
DB08791	1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE	Small Molecule	MET	1
DB08865	Crizotinib	Small Molecule	ALK, MET	2
DB08875	Cabozantinib	Small Molecule	KDR, MET, RET	3
DB12200	Tivantinib	Small Molecule	MET	1
DB12267	Brigatinib	Small Molecule	ABL1, ALK, EGFR, ERBB2, ERBB4, FLT3, IGF1R, INSR, MET	9
DB12742	Amuvatinib	Small Molecule	FLT3, KIT, MET, PDGFRA, RAD51, RET	6

Browse MET